Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism

被引：61

作者：

Tang, Jun ^{[1
,2
]}

Ye, Lifang ^{[1
,2
]}

Yan, Qiqi ^{[1
,2
]}

Zhang, Xin ^{[1
,2
]}

Wang, Lihong ^{[1
,2
]}

机构：

[1] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China

[2] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Cardiovasc Med, Peoples Hosp, Hangzhou, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2022年 / 13卷

基金：

中国国家自然科学基金;

关键词：

sodium-glucose cotransporter 2 inhibitor; heart failure; diuretic effect; natriuresis; glycosuria; HEART-FAILURE; DIABETES-MELLITUS; SGLT2; INHIBITORS; BLOOD-PRESSURE; DAPAGLIFLOZIN TREATMENT; ARTERIAL STIFFNESS; KIDNEY-DISEASE; DOUBLE-BLIND; WEIGHT-LOSS; FAT MASS;

D O I：

10.3389/fphar.2022.800490

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sodium-glucose cotransporter 2 (SGLT2) inhibitors exert hypoglycemic and diuretic effects by inhibiting the absorption of sodium and glucose from the proximal tubule. Currently available data indicate that SGLT2 inhibitors transiently enhance urinary sodium excretion and urinary volume. When combined with loop diuretics, SGLT2 inhibitors exert a synergistic natriuretic effect. The favorable diuretic profile of SGLT2 inhibitors may confer benefits to volume management in patients with heart failure but this natriuretic effect may not be the dominant mechanism for the superior long-term outcomes observed with these agents in patients with heart failure. The first part of this review explores the causes of transient natriuresis and the diuretic mechanisms of SGLT2 inhibitors. The second part provides an overview of the synergistic effects of combining SGLT2 inhibitors with loop diuretics, and the third part summarizes the mechanisms of cardiovascular protection associated with the diuretic effects of SGLT2 inhibitors.

引用

页数：12

共 122 条

[61] Effect of Dapagliflozin Treatment on the Expression of Renal Sodium Transporters/Channels on High-Fat Diet Diabetic Mice [J].

Ma, Chao ;

de Baaij, Eroen H. F. ;

Millar, Paul J. ;

Gault, Victor A. ;

de Galan, Bastiaan E. ;

Bindels, Rene J. M. ;

Hoenderop, Joost G. J. .

NEPHRON, 2019, 142 (01) :51-60

[62] 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction A Report of the American College of Cardiology Solution Set Oversight Committee [J].

Maddox, Thomas M. ;

Januzzi, James L. ;

Allen, Larry A. ;

Breathett, Khadijah ;

Butler, Javed ;

Davis, Leslie L. ;

Fonarow, Gregg C. ;

Ibrahim, Nasrien E. ;

Lindenfeld, JoAnn ;

Masoudi, Frederick A. ;

Motiwala, Shweta R. ;

Oliveros, Estefania ;

Patterson, J. Herbert ;

Walsh, Mary Norine ;

Wasserman, Alan ;

Yancy, Clyde W. ;

Youmans, Quentin R. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (06) :772-810

[63] Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction [J].

Maeda, K ;

Tsutamoto, T ;

Wada, A ;

Hisanaga, T ;

Kinoshita, M .

AMERICAN HEART JOURNAL, 1998, 135 (05) :825-832

[64] Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation [J].

Marton, Adriana ;

Kaneko, Tatsuroh ;

Kovalik, Jean-Paul ;

Yasui, Atsutaka ;

Nishiyama, Akira ;

Kitada, Kento ;

Titze, Jens .

NATURE REVIEWS NEPHROLOGY, 2021, 17 (01) :65-77

[65] Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease [J].

Maruyama, Takashi ;

Takashima, Hiroyuki ;

Oguma, Hidetaka ;

Nakamura, Yoshihiro ;

Ohno, Michiko ;

Utsunomiya, Kei ;

Furukawa, Tetsuya ;

Tei, Ritsukou ;

Abe, Masanori .

DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (12) :713-720

[66] Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume [J].

Masuda, Takahiro ;

Muto, Shigeaki ;

Fukuda, Keiko ;

Watanabe, Minami ;

Ohara, Ken ;

Koepsell, Hermann ;

Vallon, Volker ;

Nagata, Daisuke .

PHYSIOLOGICAL REPORTS, 2020, 8 (02)

[67] Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat [J].

Masuda, Takahiro ;

Watanabe, Yuko ;

Fukuda, Keiko ;

Watanabe, Minami ;

Onishi, Akira ;

Ohara, Ken ;

Imai, Toshimi ;

Koepsell, Hermann ;

Muto, Shigeaki ;

Vallon, Volker ;

Nagata, Daisuke .

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2018, 315 (03) :F653-F664

[68] Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes [J].

Matsutani, Daisuke ;

Sakamoto, Masaya ;

Kayama, Yosuke ;

Takeda, Norihiko ;

Horiuchi, Ryuzo ;

Utsunomiya, Kazunori .

CARDIOVASCULAR DIABETOLOGY, 2018, 17

[69] Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease [J].

Mazer, C. David ;

Hare, Gregory M. T. ;

Connelly, Philip W. ;

Gilbert, Richard E. ;

Shehata, Nadine ;

Quan, Adrian ;

Teoh, Hwee ;

Leiter, Lawrence A. ;

Zinman, Bernard ;

Juni, Peter ;

Zuo, Fei ;

Mistry, Nikhil ;

Thorpe, Kevin E. ;

Goldenberg, Ronald M. ;

Yan, Andrew T. ;

Connelly, Kim A. ;

Verma, Subodh .

CIRCULATION, 2020, 141 (08) :704-707

[70]

McDonagh Theresa A, 2022, Rev Esp Cardiol (Engl Ed), V75, P523, DOI [10.1093/eurheartj/ehab368, 10.1002/ejhf.2333, 10.1016/j.rec.2022.05.005]

← 2 3 4 5 6 7 8 9 10 11 →